نتایج جستجو برای: her2

تعداد نتایج: 14568  

2016
Yao Huang David J Burns Benjamin E Rich Ian A MacNeil Abhijit Dandapat Sajjad M. Soltani Samantha Myhre Brian F Sullivan Leo T Furcht Carol A Lange Sara A Hurvitz Lance G Laing

The results of clinical trials evaluating the efficacy of HER2 inhibitors in patients with breast cancer indicate that the correlation between HER2 receptor levels and patient outcomes is as low as 50%. The relatively weak correlation between HER2 status and response to HER2-targeting drugs suggests that measurement of HER2 signaling activity, rather than absolute HER2 levels, may more accurate...

Journal: :Journal of immunotherapy and precision oncology 2023

ABSTRACT HER2-targeted therapy with the HER2 monoclonal antibody trastuzumab has achieved impressive outcomes in first-line settings of patients advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma overexpressing HER2. However, considering that a substantial proportion those eventually relapses, as well relatively limited performance agents second-line settings, deeper understand...

Journal: :middle east journal of cancer 0
bahareh owrangi shiraz institute for cancer research, school of medicine, shiraz university of medical sciences, shiraz, iran mojtaba habibagahi department of immunology, school of medicine, shiraz university of medical sciences, shiraz, iran ahmad hosseini shiraz institute for cancer research, school of medicine, shiraz university of medical sciences, shiraz, iran negin fazelzadeh haghighi department of immunology, school of medicine, shiraz university of medical sciences, shiraz, iran mohsen mardani department of immunology, school of medicine, shiraz university of medical sciences, shiraz, iran abdolrasoul talei department of surgery, school of medicine, shiraz university of medical sciences, shiraz, iran

background : mdm2, e-cadherin, survivin and her2 genes are involved in the regulation of normal cell growth. however, any crucial change in their expression levels can convert a normal cell into a cancer cell. numerous studies have identified alterations of these gene expression levels in various cancers, particularly in breast cancer. thus, they may be used as diagnostic biomarkers. in this ex...

Background and aims:  Gastric malignancies have the fourth place among the most prevalent cancers. In many cancers, overexpressing of HER2/neu gene has been observed with a poor prediction. Up to now, there is a little information about the duplication of HER2/neu gene in gastric cancer using MLPA method. The present study aimed to investigate the frequency of mutations resulting from ampl...

Journal: :Cancers 2023

Background: Elucidating the clinical features of metastatic breast cancer (MBC) patients with an exceptionally favorable prognosis may offer insights to improve survival more typical patients. Methods: We collected comprehensive real-world data on clinicopathologic characteristics, treatments, and outcomes 110 consecutive MBC who survived for over ten years from warehouse Samsung Medical Center...

2014
Mari Hosonaga Yoshimi Arima Eiji Sugihara Norio Kohno Hideyuki Saya

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways. However, resistance to HER2-targeted therapy remains a major clinical problem. Overexpression of CD24 has been detected in many cancers and is associated with a poor ...

Ardeshir Ghavamzadeh, Fatemeh Nevisi, Gholamreza Javadi, Hossein Pashaiefar, Kamran Alimoghaddam, Marjan Yaghmaie, Masoud Iravani,

Background: Gastric cancer (GC) is considered as one of the most common types of cancer worldwide with poor prognosis and generally limited treatment options. Recent studies have indicated that HER2, MDM2, MYC, MET, and TP53 play an important role in the development of gastric cancer. Therefore, the aim of this study was to evaluate the incidence of amplification/deletion of these genes in pati...

Journal: :Human pathology 2017
Yoshifumi Shimada Ryoma Yagi Hitoshi Kameyama Masayuki Nagahashi Hiroshi Ichikawa Yosuke Tajima Takuma Okamura Mae Nakano Masato Nakano Yo Sato Takeaki Matsuzawa Jun Sakata Takashi Kobayashi Hitoshi Nogami Satoshi Maruyama Yasumasa Takii Takashi Kawasaki Kei-Ichi Homma Hiroshi Izutsu Keisuke Kodama Jennifer E Ring Alexei Protopopov Stephen Lyle Shujiro Okuda Kohei Akazawa Toshifumi Wakai

HER2-targeted therapy is considered effective for KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (CRC). In general, HER2 status is determined by the use of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Comprehensive genomic sequencing (CGS) enables the detection of gene mutations and copy number alterations including KRAS mutation and HER2 amp...

Objective(s): Expression of HER2 in gastric carcinoma has direct prognostic and therapeutic implications in patient management. The aim of this study is to determine whether a relationship exists between standardized uptake value (SUV) and expression of HER2 in advanced gastric carcinoma. Methods: We analyzed the 18F-FDG PET/CT results of 109 patients that underwent gastrectomy for advanced gas...

Objective(s): Development of molecules that specifically recognize cancer cells is one of the major areas in cancer research. Human epidermal growth factor receptor 2 (HER2) is specifically expressed on the surface of breast cancer cells. HER2 is associated with an aggressive phenotype and poor prognosis. In this study we aimed to isolate RNA aptamers that specifically bind to HER2 overexpressi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید